Exact Mass: 411.1194552
Exact Mass Matches: 411.1194552
Found 217 metabolites which its exact mass value is equals to given mass value 411.1194552
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Mandipropamid
C23H22ClNO4 (411.1237282000001)
D016573 - Agrochemicals D010575 - Pesticides CONFIDENCE standard compound; EAWAG_UCHEM_ID 3061
Altanserin
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist Altanserin can synthesize Fluorine-18 Altanserin. Fluorine-18 Altanserin binds to the brain 5HT2 receptors[1].
Ro 18-5364
Gonyautoxin I
Gonyautoxin I is found in mollusks. Gonyautoxin I is produced by Gonyaulax and Protogonyaulax species and isolated from shellfish. Neurotoxin, causal agent, with Saxitoxin, of shellfish poisoning. From Gonyaulax and Protogonyaulax subspecies Gonyautoxin IV is found in mollusks. D009676 - Noxae > D011042 - Poisons > D008978 - Mollusk Venoms D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins D009676 - Noxae > D011042 - Poisons > D014688 - Venoms
Tiagabine hydrochloride
C20H26ClNO2S2 (411.10934060000005)
D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D058805 - GABA Uptake Inhibitors C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent D002491 - Central Nervous System Agents > D000927 - Anticonvulsants D018377 - Neurotransmitter Agents > D018682 - GABA Agents D049990 - Membrane Transport Modulators Tiagabine hydrochloride is a potent and selective GABA reuptake inhibitor, used as an anticonvulsant agent, with IC50s of 67, 446 and 182 nM for [3H]GABA uptake in Synaptosomes, Neurons and Glia, respectively[1].
Ipratropium bromide
R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03B - Other drugs for obstructive airway diseases, inhalants > R03BB - Anticholinergics R - Respiratory system > R01 - Nasal preparations > R01A - Decongestants and other nasal preparations for topical use C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents Ipratropium bromide (Sch 1000) is a muscarinic receptor antagonist, with IC50s of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide relaxes smooth muscle, can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma[1][2][3][4][5].
7-Formyldehydrothalicsimidine
7-Formyldehydrothalicsimidine is found in beverages. 7-Formyldehydrothalicsimidine is an alkaloid from Annona purpurea (soncoya). Alkaloid from Annona purpurea (soncoya). 7-Formyldehydrothalicsimidine is found in beverages and fruits.
N6-carbamoylthreonyladenosine
N6-Carbamoyl-L-threonyladenosine is a member of the class of compounds known as purine nucleosides. Purine nucleosides are compounds composed of a purine base attached to a ribosyl or deoxyribosyl moiety. N6-Carbamoyl-L-threonyladenosine is slightly soluble (in water) and a very weakly acidic compound (based on its pKa). Within the cell, N6-carbamoyl-L-threonyladenosine is primarily located in the cytoplasm. It can also be found in the extracellular space. N6-Carbamoyl-L-threonyladenosine is a minor constituent found in human and bovine milk (PMID: 7702711). Minor constituant found in human, bovine, and goat milk
Sulfociprofloxacin
C17H18FN3O6S (411.09003000000007)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones
Cetocycline
C22H21NO7 (411.13179560000003)
N-(2(S)-(Acetylthiomethyl)-3-(2-methylphenyl)-1-oxopropyl)-L-methionine ethyl ester
C20H29NO4S2 (411.15379140000005)
Sulfo-ciprofloxacin
C17H18FN3O6S (411.09003000000007)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones
N-(4-((5-(3-(2-Aminoethyl)-1H-indol-5-yl)-1,2,4-oxadiazol-3-yl)methyl)phenyl)methanesulfonamide
C20H21N5O3S (411.1365036000001)
Acetamide, N-(((5S)-3-(3-fluoro-4-(6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-
C19H18FN7O3 (411.14550900000006)
4-[3-(trifluoromethyl)phenyl]-5-(3,4,5-trimethoxyphenyl)-4H-1,2,4-triazole-3-thiol
C18H16F3N3O3S (411.0864422000001)
N-acetylaspatyl-glutamyl-taurine-SO3
C13H21N3O10S (411.09476060000003)
nortropane-3alpha,6beta,7beta-triol 3-benzoate 7-(2-hydroxy-3-phenylpropanoate)
3,7,8-tris(4-Hydroxyphenyl)-pyrrolo[2,1-c][1,4]oxazin-1-one
Altanserin
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist Altanserin can synthesize Fluorine-18 Altanserin. Fluorine-18 Altanserin binds to the brain 5HT2 receptors[1].
4-[[4-(4-fluorophenyl)-3-piperidinyl]methoxy]-2-methoxy-, hydrogen sulfate (ester), (3S-trans)-Pheno
C19H22FNO6S (411.11518040000004)
Sulfociprofloxacin
C17H18FN3O6S (411.09003000000007)
An organosulfonic acid that is ciprofloxacin carrying a sulfo group at position 4 of the piperazine ring. It is a metabolite of ciprofloxacin. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones
Val-Trp-OH
C21H21N3O6 (411.14302860000004)
Trp-Abu-OH
C21H21N3O6 (411.14302860000004)
7-Formyldehydrothalicsimidine
(4-(N-Benzyl-N-(4-methoxybenzyl)sulfamoyl)phenyl)boronic acid
C21H22BNO5S (411.13116720000005)
N-(4-acetylphenyl)-4-hydroxy-N-[(4-methoxyphenyl)methyl]benzenesulfonamide
C22H21NO5S (411.1140376000001)
4-(4-TERT-BUTYLPHENYL)-N-(2-CHLOROPHENYL)-5-CYAN-AMIDE-4,5-DIHYDRO-1,3,4-THIADIAZOLE-2-CARBOXAMIDE
C20H18ClN5OS (411.09205280000003)
2,3,5-TRI-O-ACETYL-8-FLUORO ADENOSINE
C16H18FN5O7 (411.11902100000003)
3-Butyl-1,1,2-trimethyl-1H-benzo[e]indolium hexafluorophosphate
2-Methyl-2-propanyl (3Z,5Z)-3,5-bis(4-fluorobenzylidene)-4-oxo-1- piperidinecarboxylate
4-Aminodibenzo-18-crown-6 hydrochloride
C20H26ClNO6 (411.1448566000001)
(2s,4s)-1-t-butoxycarbonyl-2-(N-T-butoxycarbonyl-N-sulfamoylamino)methyl-4-mercapto-pyrrolidine
4(1H)-Pyridazinone, 6-methyl-3-(2-quinolinylmethoxy)-1-(3-(trifluorome thyl)phenyl)-
Methyl 1-((2-cyano-[1,1-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate
2-[(2-cyanoethyl)[4-[(2-hydroxy-4-nitrophenyl)azo]-m-tolyl]amino]ethyl acetate
C20H21N5O5 (411.15426160000004)
(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid
Thiazolidine, 2-(4-methylphenyl)-3-[(4-phenoxyphenyl)sulfonyl]- (9CI)
C22H21NO3S2 (411.09627960000006)
2,3,5-Tri-O-acetyl-2-fluoroadenosine
C16H18FN5O7 (411.11902100000003)
L-694247
C20H21N5O3S (411.1365036000001)
9-Mesityl-10-methylacridinium perchlorate
C23H22ClNO4 (411.1237282000001)
Bimiralisib
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor Bimiralisib (PQR309) is a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor with IC50s of 33 nM, 451 nM, 661 nM, 708 nM and 89 nM for PI3Kα, PI3Kδ, PI3Kβ, PI3Kγ and mTOR, respectively. Bimiralisib is an mTORC1 and mTORC2 inhibitor. Bimiralisib (PQR309) is a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor with IC50s of 33 nM, 451 nM, 661 nM, 708 nM and 89 nM for PI3Kα, PI3Kδ, PI3Kβ, PI3Kγ and mTOR, respectively. Bimiralisib is an mTORC1 and mTORC2 inhibitor.
3-(1,1-Dioxido-4h-1,2,4-Benzothiadiazin-3-Yl)-4-Hydroxy-1-(3-Methylbutyl)quinolin-2(1h)-One
C21H21N3O4S (411.1252706000001)
Bendamustine hydrochloride monohydrate
C16H24Cl3N3O3 (411.08831640000005)
4-(dimethylsulfamoyl)-N-(6,7,8,9-tetrahydro-5H-carbazol-3-ylmethyl)benzamide
Allyl-{4-[3-(4-bromo-phenyl)-benzofuran-6-yloxy]-but-2-enyl}-methyl-amine
5-(6-d-Ribitylamino-2,4-dihydroxypyrimidin-5-yl)-1-pentyl-phosphonic acid
4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
C18H16F3N3O5 (411.10420020000004)
S-{3-[(4-Anilinoquinazolin-6-YL)amino]-3-oxopropyl}-L-cysteine
C20H21N5O3S (411.1365036000001)
Methyl 3-Chloro-2-{3-[(2,5-Dihydroxy-4-Methoxyphenyl)amino]-3-Oxopropyl}-4,6-Dihydroxybenzoate
4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one
N-(2(S)-(Acetylthiomethyl)-3-(2-methylphenyl)-1-oxopropyl)-L-methionine ethyl ester
C20H29NO4S2 (411.15379140000005)
N-[[3-[3-fluoro-4-[6-(1-methyltetrazol-5-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
C19H18FN7O3 (411.14550900000006)
(6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-yl)-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]methanone
2-methyl-3-{4-[4-(trifluoromethoxy)phenoxy]phenyl}quinolin-4(1H)-one
Dichotomide XII, (rel)-
C21H21N3O6 (411.14302860000004)
A natural product found in Stellaria dichotoma var. lanceolata.
N-[3-(4-methyl-1-piperazinyl)-1,4-dioxo-2-naphthalenyl]benzenesulfonamide
C21H21N3O4S (411.1252706000001)
1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[3-fluoro-4-(1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)phenyl]urea
C19H18FN7O3 (411.14550900000006)
2-(1,5-Dimethyl-3-oxo-2-phenyl-4-pyrazolyl)-3-hydroxy-3-phenyl-1-isoindolone
4-[3-[4-[2-Furanyl(oxo)methyl]-1-piperazinyl]-2,5-dioxo-1-pyrrolidinyl]benzoic acid methyl ester
C21H21N3O6 (411.14302860000004)
3-[6,6-dimethyl-3-(methylthio)-4-oxo-5,7-dihydro-2-benzothiophen-1-yl]-N-phenyl-1-pyrazolecarboxamide
5-cyclopropyl-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)-7-(trifluoromethyl)-1,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-2-carboxamide
C18H20F3N5OS (411.13405860000006)
N-[2-(2,3-dimethylphenyl)-5,5-dioxo-4,6-dihydrothieno[3,4-c]pyrazol-3-yl]-2-methoxybenzamide
C21H21N3O4S (411.1252706000001)
N-(1,3-benzothiazol-2-yl)-2-(3-methoxyphenyl)-4-quinolinecarboxamide
N-(3,4-dimethylphenyl)-2-[[5-[3-(4-methoxyphenyl)propyl]-1,3,4-oxadiazol-2-yl]thio]acetamide
(E)-3-(4-methoxyphenyl)-N-[4-(2-methoxyphenyl)piperazine-1-carbothioyl]prop-2-enamide
2-(3-oxo-4H-1,4-benzothiazin-2-yl)acetic acid (7-methoxy-2-oxo-1-benzopyran-4-yl)methyl ester
C21H17NO6S (411.07765420000004)
1-(3,5-Dimethyl-1-piperidinyl)-2-[[2-(thiophen-2-ylmethyl)-4-quinazolinyl]thio]ethanone
2-(3-ethylphenoxy)-N-[4-(2-pyridinylsulfamoyl)phenyl]acetamide
C21H21N3O4S (411.1252706000001)
N-(1,3-benzothiazol-2-yl)-2-[[5-(4-methoxyphenyl)-4-methyl-1,2,4-triazol-3-yl]thio]acetamide
5-(4-Ethoxyphenyl)-1,3-diphenyl-3a,6a-dihydropyrrolo[3,4-c]pyrazole-4,6-dione
2-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]sulfanyl-6-ethyl-5-methylpyridine-3-carbonitrile
6-(7,8-dimethoxy-1-methyl-3-phenyl-2H-pyrazolo[3,4-c]isoquinolin-5-ylidene)-1-cyclohexa-2,4-dienone
2-(4-Ethoxy-3-methoxyphenyl)-3-(4-methoxyphenyl)-6-oxo-4-sulfanyl-1,2-dihydropyrimidine-5-carbonitrile
C21H21N3O4S (411.1252706000001)
4-[[7-Methyl-4-(phenylthio)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-2-yl]methyl]morpholine
2-[(5,6-Dimethyl-2-propyl-4-thieno[2,3-d]pyrimidinyl)thio]-1-(2-methyl-2,3-dihydroindol-1-yl)ethanone
(E)-2-(1H-benzimidazol-2-yl)-N-(furan-2-ylmethyl)-3-[3-(trifluoromethyl)phenyl]prop-2-enamide
N-{[(1S,2R)-1-carboxylato-2-hydroxypropyl]carbamoyl}adenosine
2-(4-bromophenyl)-1-(4-ethoxyphenyl)-6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepin-4-ium
(2S,3S,4S)-3-[4-[2-(2-fluorophenyl)ethynyl]phenyl]-4-(hydroxymethyl)-1-(pyridine-3-carbonyl)azetidine-2-carbonitrile
C25H18FN3O2 (411.13829799999996)
(2R,3S,4S)-3-[4-[2-(2-fluorophenyl)ethynyl]phenyl]-4-(hydroxymethyl)-1-(pyridine-3-carbonyl)azetidine-2-carbonitrile
C25H18FN3O2 (411.13829799999996)
(2R,3S,4R)-3-[4-[2-(2-fluorophenyl)ethynyl]phenyl]-4-(hydroxymethyl)-1-[oxo(3-pyridinyl)methyl]-2-azetidinecarbonitrile
C25H18FN3O2 (411.13829799999996)
(2S,3R,4S)-3-[4-[2-(2-fluorophenyl)ethynyl]phenyl]-4-(hydroxymethyl)-1-[oxo(3-pyridinyl)methyl]-2-azetidinecarbonitrile
C25H18FN3O2 (411.13829799999996)
(2S,3R,4R)-3-[4-[2-(2-fluorophenyl)ethynyl]phenyl]-4-(hydroxymethyl)-1-[oxo(3-pyridinyl)methyl]-2-azetidinecarbonitrile
C25H18FN3O2 (411.13829799999996)
(2R,3R,4R)-3-[4-[2-(2-fluorophenyl)ethynyl]phenyl]-4-(hydroxymethyl)-1-[oxo(3-pyridinyl)methyl]-2-azetidinecarbonitrile
C25H18FN3O2 (411.13829799999996)
Sodium 3-[[2-pyridin-3-yl-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidin-4-yl]amino]propanoate
(1R,2aS,8bS)-N-(4-chlorophenyl)-2-[cyclopropyl(oxo)methyl]-1-(hydroxymethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
(1S,2aR,8bR)-N-(4-chlorophenyl)-2-[cyclopropyl(oxo)methyl]-1-(hydroxymethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
(2S,3S,4R)-3-[4-[2-(2-fluorophenyl)ethynyl]phenyl]-4-(hydroxymethyl)-1-[oxo(3-pyridinyl)methyl]-2-azetidinecarbonitrile
C25H18FN3O2 (411.13829799999996)
(1S,2aS,8bS)-N-(4-chlorophenyl)-2-[cyclopropyl(oxo)methyl]-1-(hydroxymethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
(1R,2aR,8bR)-N-(4-chlorophenyl)-2-[cyclopropyl(oxo)methyl]-1-(hydroxymethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
(2-amino-5,10,10-trihydroxy-6-imino-9-sulfooxy-3a,4,8,9-tetrahydro-1H-pyrrolo[1,2-c]purin-4-yl)methyl carbamate
2-(4-(4-Methoxyphenyl)-6-phenyl-2-pyrimidinylamino)benzoic acid methyl ester
2,4-Dibenzyl-4,4A-dihydro-1H-(1,3,5)triazino(1,2-A)quinoline-1,3,6(2H,5H)-trione
N-[(9-beta-D-ribofuranosylpurin-6-yl)carbamoyl]threonate
A hydroxy monocarboxylic acid anion that is the conjugate base of N-[(9-beta-D-ribofuranosylpurin-6-yl)carbamoyl]threonine, obtained by deprotonation of the carboxy group; major species at pH 7.3.
E-3620
E-3620 is a potent 5-HT3 receptor antagonist. E-3620 can be used for the research of dyskinesi and gastrointestinal motility[1][2].
VU6019650
C18H22FN3O3S2 (411.10865540000003)
VU6019650 is a potent and selective orthosteric antagonist of M5 mAChR (IC50=36 nM), can be used for opioid use disorder (OUD) relief. VU6019650 can cross blood brain barrier, potentially modulates the mesolimbic dopaminergic reward circuitry. VU6019650 blocks Oxotremorine M iodide (HY-101372A) induced increases of neuronal firing rates of midbrain dopamine neurons in the ventral tegmental area (VTA)[1][2].
2-(1-{1-acetyl-9h-pyrido[3,4-b]indol-3-yl}-n-methylformamido)-5-methoxy-5-oxopentanoic acid
C21H21N3O6 (411.14302860000004)
6',7'-dimethoxy-2'-methyl-3',4',6,8-tetrahydro-2h-spiro[indeno[4,5-d][1,3]dioxole-7,1'-isoquinolin]-8-yl acetate
(1r,4ar,12as)-3-acetyl-1-amino-4,4a,6,7-tetrahydroxy-8,11-dimethyl-12,12a-dihydro-1h-tetracene-2,5-dione
C22H21NO7 (411.13179560000003)
[5,10,10-trihydroxy-2,6-diimino-9-(sulfooxy)-hexahydropyrrolo[1,2-c]purin-4-yl]methoxycarboximidic acid
3-[(1s)-1-[(5r)-6-hydroxy-5-[(methylsulfanyl)methyl]-3-[(1e)-2-oxocyclopent-3-en-1-ylidene]-4,5-dihydro-2h-pyrazin-2-yl]ethyl]-1-methyl-3h-indol-2-one
(2s,3r,4s,5r,6s)-6-(4-{[(2-ethoxy-2-sulfanylideneethylidene)amino]methyl}phenoxy)-4,5-dihydroxy-2-methyloxan-3-yl acetate
(3s)-3-[(1s)-1-[(2s,5r)-6-hydroxy-5-[(methylsulfanyl)methyl]-3-[(1z)-2-oxocyclopent-3-en-1-ylidene]-4,5-dihydro-2h-pyrazin-2-yl]ethyl]-1-methyl-3h-indol-2-one
[(3as,4r,9r)-5,10,10-trihydroxy-2,6-diimino-9-(sulfooxy)-hexahydropyrrolo[1,2-c]purin-4-yl]methoxycarboximidic acid
(5s,8s,9r)-8-benzoyl-2-(5-ethylfuran-2-yl)-6,9-dihydroxy-8-methoxy-3-methyl-1-oxa-7-azaspiro[4.4]nona-2,6-dien-4-one
C22H21NO7 (411.13179560000003)
6-[2-(1,5-dihydroxy-5-methylhexyl)-1,3-thiazol-4-yl]-3-hydroxy-4,5-dimethoxypyridine-2-carboximidic acid
C18H25N3O6S (411.14639900000003)
(7s,8r)-6',7'-dimethoxy-2'-methyl-3',4',6,8-tetrahydro-2h-spiro[indeno[4,5-d][1,3]dioxole-7,1'-isoquinolin]-8-yl acetate
3-(1-{6-hydroxy-5-[(methylsulfanyl)methyl]-3-(2-oxocyclopent-3-en-1-ylidene)-4,5-dihydro-2h-pyrazin-2-yl}ethyl)-1-methyl-3h-indol-2-one
n-(4,7-dihydroxy-8-methyl-2-oxochromen-3-yl)-4-hydroxy-3-[(2s)-2-hydroxy-3-methylbut-3-en-1-yl]benzenecarboximidic acid
C22H21NO7 (411.13179560000003)
(3s)-3-[(1s)-1-[(2s,5r)-6-hydroxy-5-[(methylsulfanyl)methyl]-3-[(1e)-2-oxocyclopent-3-en-1-ylidene]-4,5-dihydro-2h-pyrazin-2-yl]ethyl]-1-methyl-3h-indol-2-one
(5r,8s,9s)-8-benzoyl-2-(5-ethylfuran-2-yl)-6,9-dihydroxy-8-methoxy-3-methyl-1-oxa-7-azaspiro[4.4]nona-2,6-dien-4-one
C22H21NO7 (411.13179560000003)
2-amino-n-{5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl}-3-(methylsulfanyl)propanimidic acid
C16H25N7O4S (411.16886500000004)
2,3,4,6,7-pentahydroxy-1h,2h,3h,4h,4ah,9h,11bh-[1,3]dioxolo[4,5-j]phenanthridin-1-yl 3-hydroxybutanoate
methyl (2s,3s,5s,6r,10s)-3,5-dihydroxy-2,6-dimethyl-21-oxo-14-oxa-8-azahexacyclo[11.6.1.1⁵,¹⁹.0²,¹⁰.0³,⁸.0¹⁷,²⁰]henicosa-1(19),13(20),15,17-tetraene-18-carboxylate
n-[6-(2-hydroxy-3,4,5-trimethoxyphenyl)-2h-naphtho[2,3-d][1,3]dioxol-5-yl]-n-methylformamide
C22H21NO7 (411.13179560000003)
(3as,4r,9r,10as)-6-amino-10,10-dihydroxy-4-[(c-hydroxycarbonimidoyloxy)methyl]-2-imino-9-(sulfooxy)-1h,3h,3ah,4h,8h,9h-pyrrolo[1,2-c]purin-5-ium-5-olate
(5r,8s,9r)-8-benzoyl-2-(5-ethylfuran-2-yl)-6,9-dihydroxy-8-methoxy-3-methyl-1-oxa-7-azaspiro[4.4]nona-2,6-dien-4-one
C22H21NO7 (411.13179560000003)
(2r)-2-amino-n-[(3s,4r)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(methylsulfanyl)propanimidic acid
C16H25N7O4S (411.16886500000004)
(1r,2r,3s,4s,4ar,11br)-2,3,4,6,7-pentahydroxy-1h,2h,3h,4h,4ah,9h,11bh-[1,3]dioxolo[4,5-j]phenanthridin-1-yl (3s)-3-hydroxybutanoate
n-(4,7-dihydroxy-8-methyl-2-oxochromen-3-yl)-4-hydroxy-3-(2-hydroxy-3-methylbut-3-en-1-yl)benzenecarboximidic acid
C22H21NO7 (411.13179560000003)
(5s,8s,9s)-8-benzoyl-2-(5-ethylfuran-2-yl)-6,9-dihydroxy-8-methoxy-3-methyl-1-oxa-7-azaspiro[4.4]nona-2,6-dien-4-one
C22H21NO7 (411.13179560000003)
8-benzoyl-2-(5-ethylfuran-2-yl)-6,9-dihydroxy-8-methoxy-3-methyl-1-oxa-7-azaspiro[4.4]nona-2,6-dien-4-one
C22H21NO7 (411.13179560000003)